Key Takeaways TGTX shares rose after preliminary Q4 and full-year 2025 revenues topped company guidance.TGTX expects 2026 revenues of $875M to$900M, including $825M to$850M from U.S. Briumvi sales.TGTX plans multiple 2026 milestones, including ENHANCE data, subcutaneous Briumvi results, and azer-cel data.TG Therapeutics’ (TGTX) shares rose nearly 7% in after-hours trading, following the release of preliminary fourth-quarter and full-year 2025 results on Jan. 13, which beat expectations.TGTX issued bullish ...